Effects of histone acetyltransferase inhibitors on L-DOPA-induced dyskinesia in a murine model of Parkinson's disease.
Young-Kyoung RyuHye-Yeon ParkJun GoYong-Hoon KimJung Hwan HwangDong-Hee ChoiJung-Ran NohMyungchull RheePyung-Lim HanChul-Ho LeeKyoung-Shim KimPublished in: Journal of neural transmission (Vienna, Austria : 1996) (2018)
Histone acetylation is a key regulatory factor for gene expression in cells. Modulation of histone acetylation by targeting of histone acetyltransferases (HATs) effectively alters many gene expression profiles and synaptic plasticity in the brain. However, the role of HATs on L-DOPA-induced dyskinesia of Parkinson's disease (PD) has not been reported. Our aim was to determine whether HAT inhibitors such as anacardic acid, garcinol, and curcumin from natural plants reduce severity of L-DOPA-induced dyskinesia using a unilaterally 6-hydroxydopamine (6-OHDA)-lesioned PD mouse model. Anacardic acid 2 mg/kg, garcinol 5 mg/kg, or curcumin 100 mg/kg co-treatment with L-DOPA significantly reduced the axial, limb, and orofacial (ALO) score indicating less dyskinesia with administration of HAT inhibitors in 6-OHDA-lesioned mice. Additionally, L-DOPA's efficacy was not altered by the compounds in the early stage of treatment. The expression levels of c-Fos, Fra-2, and Arc were effectively decreased by administration of HAT inhibitors in the ipsilateral striatum. Our findings indicate that HAT inhibitor co-treatment with L-DOPA may have therapeutic potential for management of L-DOPA-induced dyskinesia in patients with PD.
Keyphrases
- dna methylation
- high glucose
- gene expression
- early stage
- diabetic rats
- drug induced
- squamous cell carcinoma
- oxidative stress
- poor prognosis
- transcription factor
- genome wide
- type diabetes
- copy number
- combination therapy
- endothelial cells
- radiation therapy
- signaling pathway
- metabolic syndrome
- resting state
- rectal cancer
- adipose tissue